Paeds SAQs · clinical-pharmacology-and-therapeutics
Inhaled therapies and device selection — formative SAQs
Formative SAQs on inhaled therapies and device selection in children: matching the device to the child's age and inspiratory flow using the age-based ladder, and defending the spacer-versus-nebuliser choice in acute asthma and the device-and-technique assessment of a 'failing' inhaled corticosteroid before escalating the dose.
On this page
Study tools
Target exams
SAQ 1 — Choosing the device across childhood (10 marks, 15 minutes)
Stem: A general paediatric clinic sees three children on the same morning: an eighteen-month-old with viral wheeze, a five-year-old with preschool wheeze, and a twelve-year-old with established asthma. Outline the age-based device ladder, the breath action expected at each step, and the principle that governs each transition. [1] [3]
Model answer
The ladder and the breath action (5 marks). The devices are matched to the child's age, inspiratory flow and coordination. The infant and toddler under about four years uses a pressurised metered-dose inhaler seated in a small-volume valved holding chamber with a tightly-fitting face mask; the dose is fired into the chamber and cleared by slow tidal breathing over around six breaths per actuation, the mask held firmly to the face. The preschool child, about four to six years, moves to a spacer with a mouthpiece, taking one to two slow deep breaths with a short breath-hold per actuation; a dry-powder inhaler is usually still too demanding. The school-age child, from about six years, can use a dry-powder inhaler if inspiratory flow is adequate — one sharp, deep inhalation then a breath-hold — or continue a spacer and pMDI. The adolescent, twelve years and over, can use any device, and the choice is increasingly driven by adherence. [1] [3]
The principle governing each transition (3 marks). Each step is a clinical judgement of the individual child, not a fixed birthday. The mask-to-mouthpiece transition depends on the child forming a reliable seal around the mouthpiece for the whole dose. The spacer-to-dry-powder-inhaler transition depends on generating the inspiratory flow — roughly thirty to sixty litres per minute — needed to de-aggregate the powder. A dry-powder inhaler given to a child who cannot generate that flow delivers almost nothing. [1] [3]
Teaching and review (2 marks). Technique is taught by demonstration and return-demonstration (teach-back) at every visit, because technique drifts and the child grows out of one device into another. After an inhaled corticosteroid the child rinses and spits to prevent oral candidiasis, and the dose counter is checked. [3]
References3ShowHide
- [1]Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest, 2005.PMID 15654001
- [3]van Aalderen WM, Garcia-Marcos L, Gappa M, et al. How to match the optimal currently available inhaler device to an individual child with asthma or recurrent wheeze. NPJ Primary Care Respiratory Medicine, 2015.PMID 25568979
- [5]Cates CJ, Welsh EJ, Rowe BH Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database of Systematic Reviews, 2013.PMID 24037768